Dexmedetomidine Alleviates CCI-Induced Neuropathic Pain via Inhibiting HMGB1-Mediated Astrocyte Activation and the TLR4/NF-κB Signaling Pathway in Rats
- PMID: 32607919
- DOI: 10.1007/s12640-020-00245-6
Dexmedetomidine Alleviates CCI-Induced Neuropathic Pain via Inhibiting HMGB1-Mediated Astrocyte Activation and the TLR4/NF-κB Signaling Pathway in Rats
Abstract
To investigate the effects of dexmedetomidine on chronic constriction injury (CCI)-induced neuropathic pain and to further explore its mechanism. A CCI rat model was established and treatment with dexmedetomidine. The paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL) were monitored at different time points, and the effects of hematoxylin-eosin staining on the sciatic nerve morphology of rats were observed. Immunohistochemical and immunofluorescence analyses were used to detect the expression of high mobility group box-1 (HMGB1) protein and glial fibrillary acidic protein (GFAP), and protein fluorescence intensity of GFAP in spinal cord tissue, respectively. Moreover, the expression of HMGB1 and Toll-like receptor-4/nuclear factor kappa-B (TLR4/NF-κB) pathway-related proteins were detected by western blot assay. To verify whether dexmedetomidine alleviates CCI-induced neuropathic pain by inhibiting HMGB1-mediated astrocyte activation and the TLR4/NF-κB signaling pathway, the rats were further treated with an HMGB1 activator or antagonist. Dexmedetomidine was found to improve the pathological changes of the sciatic nerve and alleviate pain in the CCI rats. The expression of HMGB1, GFAP, TLR4, TRAF6, MyD88, and p-P65 were greatly downregulated in the spinal cord tissues of the CCI rats. In addition, a further study showed that an HMGB1 activator can reverse the inhibition of neuropathic pain behaviors of dexmedetomidine. Overexpression of HMGB1 downregulated the PWMT and PWTL and enhanced the astrocyte activity and the TLR4/NF-κB signaling pathway in CCI rats. These results indicated that dexmedetomidine can alleviate neuropathic pain in CCI rats by inhibiting HMGB1-mediated astrocyte activation and the TLR4/NF-κB signaling pathway.
Keywords: Astrocyte; Chronic constriction injury (CCI); Dexmedetomidine; HMGB1; TLR4/NF-κB.
Similar articles
-
Protective role of ethyl pyruvate in spinal cord injury by inhibiting the high mobility group box-1/toll-like receptor4/nuclear factor-kappa B signaling pathway.Front Mol Neurosci. 2022 Sep 16;15:1013033. doi: 10.3389/fnmol.2022.1013033. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36187352 Free PMC article. Review.
-
Analgesic effects of TLR4/NF-κB signaling pathway inhibition on chronic neuropathic pain in rats following chronic constriction injury of the sciatic nerve.Biomed Pharmacother. 2018 Nov;107:526-533. doi: 10.1016/j.biopha.2018.07.116. Epub 2018 Aug 13. Biomed Pharmacother. 2018. PMID: 30114636 Retracted.
-
Effects of intrathecal epigallocatechin gallate, an inhibitor of Toll-like receptor 4, on chronic neuropathic pain in rats.Eur J Pharmacol. 2012 Feb 15;676(1-3):51-6. doi: 10.1016/j.ejphar.2011.11.037. Epub 2011 Dec 7. Eur J Pharmacol. 2012. PMID: 22173123
-
Dexmedetomidine Post-Conditioning Alleviates Cerebral Ischemia-Reperfusion Injury in Rats by Inhibiting High Mobility Group Protein B1 Group (HMGB1)/Toll-Like Receptor 4 (TLR4)/Nuclear Factor kappa B (NF-κB) Signaling Pathway.Med Sci Monit. 2020 Jan 8;26:e918617. doi: 10.12659/MSM.918617. Med Sci Monit. 2020. PMID: 31912804 Free PMC article.
-
Systematic analysis of critical genes and pathways identified a signature of neuropathic pain after spinal cord injury.Eur J Neurosci. 2022 Jul;56(2):3991-4008. doi: 10.1111/ejn.15693. Epub 2022 May 27. Eur J Neurosci. 2022. PMID: 35560852 Review.
Cited by
-
Spinal HMGB1 participates in the early stages of paclitaxel-induced neuropathic pain via microglial TLR4 and RAGE activation.Front Immunol. 2024 Feb 7;15:1303937. doi: 10.3389/fimmu.2024.1303937. eCollection 2024. Front Immunol. 2024. PMID: 38384464 Free PMC article.
-
The role of astrocytes in neuropathic pain.Front Mol Neurosci. 2022 Sep 20;15:1007889. doi: 10.3389/fnmol.2022.1007889. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36204142 Free PMC article. Review.
-
Protective role of ethyl pyruvate in spinal cord injury by inhibiting the high mobility group box-1/toll-like receptor4/nuclear factor-kappa B signaling pathway.Front Mol Neurosci. 2022 Sep 16;15:1013033. doi: 10.3389/fnmol.2022.1013033. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36187352 Free PMC article. Review.
-
Dexmedetomidine Alleviates Neuropathic Pain via the TRPC6-p38 MAPK Pathway in the Dorsal Root Ganglia of Rats.J Pain Res. 2022 Aug 19;15:2437-2448. doi: 10.2147/JPR.S378893. eCollection 2022. J Pain Res. 2022. PMID: 36016537 Free PMC article.
-
Intrathecal dexmedetomidine attenuates mechanical allodynia through the downregulation of brain-derived neurotrophic factor in a mild traumatic brain injury rat model.Korean J Anesthesiol. 2023 Feb;76(1):56-66. doi: 10.4097/kja.22209. Epub 2022 Jun 28. Korean J Anesthesiol. 2023. PMID: 35760392 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
